PRVL Stock: Eli Lilly Announces Takeover Deal Worth $1.04 Billion

Eli Lilly (LLY) agreed to buy gene therapy company Prevail Therapeutics (PRVL) for $1.04 billion on Tuesday, sending PRVL stock to a record high.


The deal “checks the boxes” for Lilly, Mizuho Securities analyst Vamil Divan said in a report to clients. He noted that Lilly Chief Financial Officer Joshua Smiley has said in the past that the drug giant was looking to acquire a gene therapy player in the neuroscience space. Prevail’s lead programs are in Parkinson’s disease and dementia.

Lilly will pay $880 million upfront, valuing PRVL stock at $22.50 per share. Shareholders will also receive a contingent value right, or CVR, worth up to $4 per share for a total of $160 million. The CVR is payable when the first Prevail product gains regulatory approval.

On today’s stock market, PRVL stock charged up 82% to 22.75. Lilly stock popped 6% to 167.43.

PRVL Stock Rockets On Takeover

Piper Sandler analyst Christopher Raymond downgraded PRVL stock to a neutral rating on the takeover news. The deal is “not so surprising in retrospect,” he said in his note to clients.

“With neuro a core therapeutic area for Lilly and with management commentary foreshadowing interest in gene therapy partnerships and acquisitions as recently as September, this move makes sense and we expect the deal to close on time in the first quarter,” he said.

The news is also likely to spark other gene therapy stocks, not just PRVL stock, he said. To that point, shares of Uniqure (QURE) lifted 3.1% to 47.86.

“While there had been a spate of gene therapy deals, the last year has seen the space take a bit of a pause coincident with some gene therapy setbacks,” he said. “Today’s news indicates that strategic interest in the technology has not waned.”

See also  Stock Futures: Check Premarket Prices For Dow Futures, S&P 500 Futures, Nasdaq Futures

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Moderna Stock Rises As FDA Appears Ready To Authorize Covid Vaccine

Is Pfizer Stock A Buy After FDA Authorizes Covid Vaccine?

Learn How To Time The Market With IBD’s ETF Market Strategy

Get Timely Buy & Sell Alerts With IBD Leaderboard

Watch IBD’s Investing Strategies Show For Actionable Market Insights

View more information:

See more articles in category: Finance

Leave a Reply

Check Also
Back to top button